Efficacy of trastuzumab-based therapy after disease progression on lapatinib based therapy in heavily pretreated HER2-positive metastatic breast cancer patients.

Uncu, DoganBayoglu, Ibrahim VedatArslan, Ulku YalcintasKucukoner, MehmetArtac, MehmetKoca, DoganOguz, Arzu2024-02-232024-02-2320140732-183X1527-7755https://doi.org/10.1200/jco.2014.32.15_suppl.e11586https://hdl.handle.net/20.500.12452/1507650th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 30-JUN 03, 2014 -- Chicago, IL[Abstract Not Availabe]eninfo:eu-repo/semantics/closedAccess[Keyword Not Available]Efficacy of trastuzumab-based therapy after disease progression on lapatinib based therapy in heavily pretreated HER2-positive metastatic breast cancer patients.Conference Object3215Q1WOS:000358613200080Q110.1200/jco.2014.32.15_suppl.e11586